Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865135 · ClinicalTrials.gov registry record · Phase 1
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
A Phase 1 study of Cancer of Head and Neck and Cancer of Cervix, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02865135 is a Phase 1 study of Cancer of Head and Neck and Cancer of Cervix that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 11 participants, below the 248-participant average among 9 other Cancer of Head and Neck trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02865135, a Phase 1 study of Cancer of Head and Neck and Cancer of Cervix, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A\*02).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG DPX-E7 vaccine
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2023-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02865135
The ClinicalTrials.gov registry entry for NCT02865135 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 248-participant average among 9 other Cancer of Head and Neck trials with a reported enrollment target (96% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer of Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT02865135 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02865135 about?
NCT02865135 is a clinical study titled "Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer". This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A\*02).
What is the current status of trial NCT02865135?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-03-30. Estimated completion is 2023-02-06.
What conditions does trial NCT02865135 study?
This clinical trial studies the following conditions: Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus.
What interventions are being tested in trial NCT02865135?
The interventions under investigation include: Cyclophosphamide (DRUG), DPX-E7 vaccine (DRUG).
Who is sponsoring clinical trial NCT02865135?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02865135 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multicenter Cancer Biospecimen Collection Study
RECRUITING
-
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Comprehensive Approach to Head and Neck Cancer Prehabilitation
ACTIVE NOT RECRUITING · NA
-
Onco-primary Care Networking to Support TEAM-based Care
ACTIVE NOT RECRUITING · NA
-
Adaptive Radiation Therapy for Head & Neck Cancer Patients
COMPLETED · NA
-
The Gut Microbiome As an Indicator of Readiness for Head & Neck Cancer Surgery
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.